Core Viewpoint - DIZHE Pharmaceutical (688192.SH) is pursuing an "A+H" listing by submitting an application to the Hong Kong Stock Exchange, aiming to raise funds for clinical development, sales, and operational expenses, while currently being in the commercialization phase with two approved products [2][3]. Financial Performance - The company raised approximately 2.1 billion yuan in its 2021 IPO and 1.8 billion yuan through a private placement in April 2025 [2]. - DIZHE expects to achieve revenue of around 800 million yuan in 2025, representing a year-on-year growth of approximately 122.28%, with a projected net loss of about 770 million yuan [2][5]. - The company reported a net profit of approximately -1.1 billion yuan in 2023 and -846 million yuan in 2024, with an expected reduction in net loss by about 75.96 million yuan in 2025 [7]. Product Pipeline and Market Strategy - DIZHE has two approved products, Shuwotini (舒沃哲) and Gelixitini (高瑞哲), which are expected to significantly enhance patient accessibility after being included in the national medical insurance catalog [4][5]. - The company is focusing on expanding the indications for its existing products and advancing its pipeline, which includes seven products currently in clinical stages [8]. R&D Investment and Challenges - DIZHE is in the early stages of commercialization and continues to incur significant R&D expenses, with an expected R&D expenditure of around 860 million yuan in 2025, reflecting a year-on-year increase of approximately 18.84% [7]. - The company is facing challenges in achieving positive operating cash flow, as it continues to invest heavily in R&D while striving for commercial profitability [6][8]. Market Position and Future Outlook - DIZHE aims to leverage its products' inclusion in the medical insurance directory to enhance market penetration and drive revenue growth, with a sales expense ratio significantly reduced to 72% in the first three quarters of 2025 [6]. - The company is committed to ensuring the advancement of its core global pipeline and key market development while maintaining a focus on sustainable high-quality profitability [8][9].

Group 1: Core Insights - The article discusses the recent trend of Chinese pharmaceutical companies, including Dizhe Pharmaceutical, applying for listings on the Hong Kong Stock Exchange (HKEX), marking a new wave of "A+H" listings since 2025 [1][2] - Policy support from the China Securities Regulatory Commission (CSRC) and HKEX has facilitated this trend, with measures such as fast-track approvals for A-share companies and dedicated services for tech and biotech firms [1][2] - The drive for A+H listings is also fueled by companies' need for diversified capital channels to mitigate A-share market volatility and to support significant R&D investments and international commercialization efforts [2] Group 2: Company-Specific Developments - Dizhe Pharmaceutical aims to enhance its global strategy and brand image through its HKEX listing, which is expected to attract international investors and foster collaborations with multinational pharmaceutical companies [2][4] - Despite projected revenue growth from 1 billion yuan in 2023 to 800 million yuan in 2025, Dizhe Pharmaceutical anticipates a net loss of 770 million yuan in 2025, highlighting the ongoing challenge of high R&D and sales expenses [3][5] - The company is actively advancing its core products, with ongoing clinical trials and plans to expand indications, while also focusing on improving operational efficiency and reducing sales expense ratios [4][5] Group 3: Market Trends and Challenges - The A+H listing trend is expected to continue into 2026, but there may be a significant differentiation between leading companies and mid-tier firms, with the latter facing greater pressure [3][10] - There are rumors of tightening listing requirements for HKEX, potentially raising the market capitalization threshold to 30 billion yuan, which could impact the number of companies able to list [6][7][8] - The HKEX has seen a substantial increase in IPO activity, with 117 companies listed in 2025, raising a total of 285.69 billion HKD, indicating a robust market despite potential pressures from increased supply [9][10]

Core Viewpoint - The company, Dize Pharmaceutical, is pursuing a listing on the Hong Kong Stock Exchange to enhance its global strategy, improve its international brand image, and strengthen its core competitiveness, rather than solely for fundraising purposes [1]. Group 1 - The company has successfully completed a targeted private placement and is now planning to issue H-shares [1]. - The primary goal of the Hong Kong listing is to deepen the company's global strategic layout and attract international investors [1]. - The company aims to leverage the advantages of dual listings to facilitate cooperation and communication with multinational pharmaceutical companies [1].

证券代码：688192 证券简称：迪哲医药 公告编号：2026-007 迪哲（江苏）医药股份有限公司 2022 年限制性股票激励计划首次授予的第二类激励对 象第二个归属期部分归属、预留授予的激励对象第一个 归属期部分归属结果暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上 市股数为614,375股。 本次股票上市流通总数为614,375股。 本次股票上市流通日期为2026 年 2 月 2 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分 公司有关业务规则的规定，迪哲（江苏）医药股份有限公司（以下简称"公司"）于 近日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》， 公司完成了 2022 年限制性股票激励计划（以下简称"限制性股票激励计划"）首次 授予的第二类激励对象第二个归属期部分归属、预留授予的激励对象第一个归属 期部分归属的股份登记工作，现将有关情况公告如下： 一、本次限制性股票归属的决策 ...

海外市场的突破性拓展成为业绩增长的核心引擎。2025年全球生物医药BD交易总额达1356.55亿美元，涉及157起交易，中国首次超越美国成为全球BD交易 最活跃市场。龙头企业纷纷通过海外授权与市场扩张斩获增量，三生国健凭借与辉瑞达成的707项目合作，获得约28.90亿元首付款收入，预计2025年归母净 利润同比增长311.35%至29亿元。CXO龙头药明康德表现亮眼，预计2025年归母净利润191.51亿元，同比激增102.65%，其"一体化、端到端"CRDMO模式持 续吸引全球客户，海外订单复苏态势显著。通化东宝的国际化战略成效凸显，胰岛素制剂已在5个新兴市场国家获批，门冬胰岛素美国BLA获FDA受理，出 口收入成为业绩重要增长点。和众汇富观察发现，国产药企正从"快速跟进"向"全球新"输出转型，出海赛道逐渐成为板块估值提升的核心主线。 截至2026年1月26日，Wind数据显示已有逾90家A股生物医药公司披露2025年业绩预告，其中53家预计实现盈利，14家公司净利润增幅下限超100%，多家企 业实现扭亏为盈或大幅减亏。在行业景气度持续回暖、海外市场加速突破及政策红利密集释放的多重支撑下，A股生物医药板块正 ...

Core Insights - The innovative drug Shuwotini tablets, which targets a rare mutation in non-small cell lung cancer, has won the first prize in Jiangsu Province's Science and Technology Progress Award, highlighting its significant breakthrough in original innovation and clinical application [1] - Shuwotini tablets are the first and only drug approved for the EGFR 20 insertion mutation, receiving market approval in China in August 2023 and subsequently being included in the national medical insurance directory, significantly reducing patient costs [1] - The award recognizes the project's contributions to technological innovation and its impact on economic and social development, emphasizing the comprehensive strength of the research and development company in key technology breakthroughs and results transformation [1] Company and Industry Developments - The company, Dizhe Pharmaceutical, aims to continue addressing unmet clinical needs through technological innovation, accelerating the delivery of globally competitive original innovations to benefit patients worldwide [2] - The drug is expected to gain international recognition, as it was approved by the U.S. FDA in 2025, marking it as the first independently developed innovative drug from China to be approved in the U.S. and included in the National Comprehensive Cancer Network guidelines for non-small cell lung cancer [1]

[Table_Reportdate] 2026年01月27日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 陈伟业 cwy@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20260127 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [table_summary] ➢ 1.药品零售新政出台，赋能行业高质量发展——医药生物行业周报（2026/01/19- 2026/01/25） ➢ 2.2026年全球AI服务器出货同比有望增超28%，AI相关芯片涨价持续——电子行业周报 2026/1/19-2025/1/25 ➢ 1.商务部：将优化实施消费品以旧换新，促进家电等大宗耐用商品消费 ➢ 2.上期所调整白银、锡期货相关合约交易限额 ➢ 3.香港特别行政区行 ...

Regulatory Actions - The China Securities Regulatory Commission (CSRC) issued its first fine of the year targeting market manipulation, with individual Yu Han penalized over 1 billion yuan for manipulating the stock price of "Doctor Glasses" [1] - Zhejiang Securities Regulatory Bureau is investigating misleading statements in the restructuring plan of "Sunflower" [1] - The Shenzhen Stock Exchange is closely monitoring *ST Lifan and *ST Changyao for suspected false financial reporting, indicating a strong regulatory stance against market violations [1] Banking Sector - Several banks have reduced their operating loan interest rates, with some as low as 2.31%, reflecting a nearly 20 basis point decrease from the previous month [1] - The competition among banks for quality small and micro-enterprise clients has intensified, leading to a price war in the lending market [1] - The financial sector is under pressure to balance price competition with sustainable operations, particularly for smaller banks with weaker client bases [1] Consumer Loan Policies - The implementation period for the personal consumption loan interest subsidy policy has been extended to December 31, 2026, with adjustments made to include credit card installment plans [2] - Current consumer loan rates are reported to be as low as 3%, with funds primarily allocated for home renovations, vehicle purchases, and travel [2] Biopharmaceutical Industry - Over 50 A-share biopharmaceutical companies are expected to report profits in 2025, driven by improving industry conditions and favorable policies [3] - As of January 26, 2023, 53 companies have issued profit forecasts, with 14 companies expecting to double their net profits [3] Lithium Market - The lithium carbonate market is expected to return to a tight balance by 2026, despite recent volatility in futures contracts [4] - Supply chain improvements and new mining licenses are anticipated, although challenges remain in waste management [4] Aviation Industry - COMAC plans to increase the production and delivery of its C919 narrow-body aircraft, targeting the delivery of 28 or more units this year [4] Technology and Research - China has achieved a record in superconducting magnet technology with a field strength of 35.6 Tesla, marking a significant advancement in high-temperature superconductors [5] - A study from the National University of Singapore has identified a key protein, DMTF1, that can restore the regenerative capacity of aging neural stem cells, offering potential for new therapies against brain aging [5] Alcohol Industry - Moutai has relaxed its requirements for distributors regarding payment for sauce-flavored liquor, allowing orders based on actual conditions to prevent excessive inventory [6] Corporate Developments - JD Smart Manufacturing has submitted a listing application to the Hong Kong Stock Exchange [6] - Anta Sports plans to acquire a 29.06% stake in PUMA SE for approximately 12.278 billion yuan [6] - Youkeshu intends to change its name to "Xingyun Technology" to better reflect its strategic direction [7] - Fuyijie expects a significant loss for 2025, with specific shareholders planning to liquidate their holdings [8] - Sunny Optical Technology has submitted a listing application for the spin-off of its automotive optical business [8] - Huakong Saige anticipates a net loss of 97 million to 120 million yuan for 2025 due to various operational challenges [9] - Guoen Co., Ltd. has set a preliminary price range for its H-share issuance between 34 and 42 Hong Kong dollars [9] Stock Market Performance - U.S. stock indices closed higher, with the Nasdaq up 0.43%, the Dow Jones up 0.64%, and the S&P 500 up 0.5%, driven by strong durable goods data [10] - The U.S. dollar has seen a decline, while gold prices have reached historical highs, with significant fluctuations in the commodities market [10]

MACD金叉信号形成，这些股涨势不错！ 受益于行业景气度日渐回暖、海外市场持续开拓、医药利好政策陆续落地，A股生物医药公司2025年在 韧性发展中不断交出创新的成绩单。Wind数据显示，截至1月26日18时，已有超过90家A股生物医药公 司发布2025年业绩预告，共有53家公司预计实现盈利。从预告净利润增幅下限来看，有14家公司预计净 利润倍增（剔除扭亏、减亏）。此外，以岭药业、楚天科技等10家公司预计实现扭亏为盈，迪哲医药、 盟科药业等14家公司同比实现减亏。（上证报） ...

Core Insights - The A-share biopharmaceutical companies are expected to deliver innovative results in 2025, benefiting from industry recovery, overseas market expansion, and favorable pharmaceutical policies [2] - Over 90 A-share biopharmaceutical companies have released performance forecasts for 2025, with 53 companies expected to be profitable [2] - Among the profit forecasts, 14 companies anticipate a net profit increase of over 100%, while 10 companies expect to turn losses into profits [3][2] Group 1: Performance Growth Drivers - Sales volume growth and internal cost reduction are key factors for the significant profit increases among the companies [4] - Shanghai Yizhong leads with a projected net profit increase of 760.18% to 903.54%, expecting a net profit of 60 million to 70 million yuan in 2025 due to its core product being included in the national medical insurance directory [4] - Yuheng Pharmaceutical anticipates a net profit of 350 million to 420 million yuan, a year-on-year increase of 50.37% to 80.44%, driven by steady sales growth of its products [4] - Nawei Technology expects a net profit of 128 million to 145 million yuan, a year-on-year increase of 54.51% to 75.03%, focusing on market strategies in key sectors [4][5] Group 2: International Market Expansion - International business is a significant growth driver for biopharmaceutical companies [6] - WuXi AppTec, a leading CXO company, forecasts a revenue of 45.456 billion yuan, a year-on-year increase of approximately 15.84%, and a net profit of 19.151 billion yuan, a 102.65% increase [6] - Ganli Pharmaceutical expects a net profit of 1.1 billion to 1.2 billion yuan, a year-on-year increase of 78.96% to 95.23%, attributed to steady growth in domestic and international revenues [6] Group 3: Innovation and Recovery - Several innovative drug companies are entering a recovery phase, with many turning losses into profits or significantly reducing losses [8] - BeiGene expects a full-year operating profit for 2025, with revenue projections between 36.2 billion and 38.1 billion yuan, reflecting an upward adjustment from previous estimates [8] - DiZhe Pharmaceutical anticipates a revenue of 800 million yuan, a year-on-year increase of 122.28%, with a reduced net loss of 770 million yuan [9]